Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kingworld Medicines Group Limited (1110.HK)
Shenzhen, CN
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +2.41% | -7.61% | -18.27% | -16.67% | -18.27% | -29.17% | -50.58% | -46.88% | -66.27% | -58.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-13.6% Q4'25: -2.5% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%-73.4% Q4'25: +4,550.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+5.1% Q4'25: +9.6% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+6.2% Q4'25: +9.1% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.5% Q4'25: +13.9% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%+1.8% Q4'25: +1.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×6.03× Q4'25: 2.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|---|---|
| Revenue |
685.56M
est: 640.74M (+7.0%)
|
1.05B
est: 912.74M (+15.4%)
|
1.03B
est: 980.07M (+5.2%)
|
1.08B
est: 1.38B (-21.9%)
|
| EBITDA |
79.94M
est: 81.11M (-1.4%)
|
125.51M
est: 113.27M (+10.8%)
|
135.31M
est: 124.07M (+9.1%)
|
116.18M
est: 174.85M (-33.6%)
|
| EBIT |
78.51M
est: 61.23M (+28.2%)
|
102.01M
est: 85.50M (+19.3%)
|
109.54M
est: 93.66M (+17.0%)
|
87.38M
est: 131.99M (-33.8%)
|
| Net Income |
51.03M
est: 43.23M (+18.0%)
|
46.97M
est: 41.89M (+12.1%)
|
51.06M
|
41.01M
|
| SGA |
108.60M
est: 148.60M (-26.9%)
|
224.67M
est: 207.51M (+8.3%)
|
251.42M
est: 227.30M (+10.6%)
|
251.43M
est: 320.34M (-21.5%)
|
| EPS |
0.08
est: 0.08 (+9.2%)
|
0.07
est: 0.07 (-0.7%)
|
0.08
|
0.07
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li Sheng Zhao | Co-Founder, Chairman & Chief Executive Officer | 2M | male |
| Lok San Chan | Co-Founder & Executive Director | 2M | female |
| Xuhua Zhou | Executive Director | 479.2K | male |
| Danna Fang | Financial Manager of SZ Kingworld Medicine Company Limited | — | female |
| Wan Chan | Financial Controller & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1110.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
